Angiotensin receptor blocker use in older adults with hypertension was associated with slower yearly global cognitive decline compared to non-users (β= 0.027; 95% CI -0.003 to 0.057).
Cohort (n=776)
Do specific antihypertensive medication classes reduce the risk of dementia and cognitive decline in older adults with hypertension?
Angiotensin receptor blockers (ARBs) may be superior to other antihypertensive classes in preserving cognitive function in older adults with hypertension.
Estimación del efecto: β= 0.027 (95% CI -0.003, 0.057)
BACKGROUND: It is unclear whether the main antihypertensive medication classes (diuretics, calcium channel blockers, beta-blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers (ARBs)) are associated with different risks of cognitive decline. Published evidence is conflicting and stems mainly from observational studies. OBJECTIVE: To investigate the differential effects of antihypertensives on the risks of developing dementia and cognitive decline, with a specific focus on the vascular component of the mechanisms underlying these interactions. METHODS: Older adults with a history of hypertension and without dementia were drawn from the population-based HELIAD cohort. Age-, gender-, education-, and antihypertensive medication- (five dichotomous exposures) adjusted Cox proportional-hazards models and generalized estimating equations were performed to appraise the associations of baseline antihypertensive therapy with dementia incidence and cognitive decline (quantified using a comprehensive neuropsychological battery). Analyses were subsequently adjusted for clinical vascular risk (dyslipidemia, diabetes mellitus, smoking, cardiovascular, and cerebrovascular history) and genetic susceptibility to stroke (using polygenic risk scores generated according to the MEGASTROKE consortium GWAS findings). RESULTS: A total of 776 predominantly female participants (73.61±4.94 years) with hypertension and a mean follow-up of 3.02±0.82 years were analyzed. Baseline treatment was not associated with the risk of incident dementia. ARB users experienced a slower yearly global cognitive 2.5% of a SD, 95% CI = (0.1, 4.9) and language 4.4% of a SD, 95% CI = (1.4, 7.4) decline compared to non-users. The fully adjusted model reproduced similar associations for both global cognitive β= 0.027, 95% CI = (-0.003, 0.057), and language decline β= 0.063, 95% CI = (0.023, 0.104). CONCLUSION: ARBs may be superior to other antihypertensive agents in the preservation of cognition, an association probably mediated by vascular-independent mechanisms.
Liampas et al. (Fri,) conducted a cohort in Hypertension without dementia (n=776). Angiotensin receptor blockers (ARBs) vs. non-users was evaluated on yearly global cognitive decline (β= 0.027, 95% CI -0.003, 0.057). Angiotensin receptor blocker use in older adults with hypertension was associated with slower yearly global cognitive decline compared to non-users (β= 0.027; 95% CI -0.003 to 0.057).